The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) backed new medicines from Hansoh, Innovent, and AstraZeneca at its November meeting, according to an EMA news roundup. The report notes that two of the three recommended therapies originated from Chinese companies. The CHMP support is an early regulatory step in the European process, affecting timelines for subsequent steps toward approval and reimbursement review. For sponsors with late-stage programs, CHMP positioning can shape investor confidence and partner strategy. The update underscores how European review activity continues to diversify among originators, including multiple China-based innovators.